GlassScriptPhysician profile
Allison B Anderson
NPI 1922384429
$7,430.26
in general payments reported to CMS, 2019-2025
43 companies · $928 in 2025
The $928 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $937 · 2022: $1,315 · 2023: $2,383 · 2024: $1,867 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,460.51 | 2021-2025 | |
| Novo Nordisk INC | $851.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $463.21 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $320.00 | 2021-2024 | Trintellix |
| Amgen INC. | $211.07 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Exact Sciences Corporation | $184.38 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $164.53 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $162.82 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $159.45 | 2023-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.28 | 2021-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $140.83 | 2021 | |
| Abbott Laboratories | $134.29 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Corium, LLC | $133.31 | 2023-2025 | Azstarys |
| Gilead Sciences, INC. | $132.15 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $127.24 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $123.65 | 2021-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $122.69 | 2023-2024 | Piqray, Kisqali |
| Idorsia Pharmaceuticals US INC | $121.91 | 2022-2024 | Quviviq |
| Astellas Pharma US INC | $103.94 | 2022-2024 | Veozah, Myrbetriq |
| Tris Pharma INC | $103.32 | 2023-2024 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $92.40 | 2022 | |
| Noven Therapeutics, LLC | $91.63 | 2023-2024 | Xelstrym, Secuado |
| Teleflex LLC | $86.59 | 2025 | Barrigel |
| Teva Pharmaceuticals USA, INC. | $85.97 | 2022-2023 | Austedo |
| Dexcom, INC. | $73.40 | 2022-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $69.22 | 2022-2023 | Tepezza |
| Dynavax Technologies Corporation | $51.18 | 2023-2024 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $49.97 | 2023-2024 | Spravato |
| Impel Pharmaceuticals INC. | $49.47 | 2022-2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $44.44 | 2023 | Lyvispah |
| Verity Pharmaceuticals INC. | $43.90 | 2024 | Tlando |
| Merck Sharp & Dohme LLC | $43.09 | 2021-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Neos Therapeutics, LP | $41.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.64 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $35.04 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.61 | 2023-2024 | Contrave |
| Mannkind Corporation | $23.51 | 2024 | |
| Supernus Pharmaceuticals, INC. | $23.41 | 2023 | Qelbree |
| Sanofi Pasteur INC. | $19.59 | 2023 | |
| Lantheus Medical Imaging, INC. | $16.45 | 2022 | |
| Medtronic, INC. | $15.96 | 2023 | Venaseal |
| Vanda Pharmaceuticals INC. | $15.89 | 2021 | |
| Phadia US INC. | $15.80 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.